Somaform's Interface Review Widens as a Second Regulator Joins In

GENEVA — What began quietly, as a single national regulator's routine post-market look at one Somaform Augmetics neural-interface line, widened this week when a second regulator in another jurisdiction opened a parallel review and asked to share the data. Nothing in the record yet suggests a fault, and Somaform stresses that point firmly: the interface in question meets every standard it was certified against, the review is precautionary, and the company is cooperating fully. But the shape of the thing has changed. A question one authority can hold as an internal matter becomes, the moment a second authority joins, a cross-border question — and cross-border questions in the augmentation sector tend not to shrink back down. At issue is the long-term behavior of a direct neural link that some five percent of humanity, and a fast-growing slice of it, now carries in their bodies for decades. "We are not alleging harm," a regulator was careful to say. "We are asking, together, a question that is easier to answer now than later." Somaform's founder, Julian Morrow, framed it as the system working as designed: an industry that puts hardware inside human skulls should expect its regulators to be patient, thorough, and, occasionally, to compare notes. The review continues. The sector, which reprices on far less, is watching.